Stocks · Healthcare · Medical - Care Facilities
Guardian Pharmacy Services, Inc. GRDN
$42.38 +3.77% Close, Oct 2, 2026 · NYSE · Market cap $2.68B
High qualityStrong trendInexpensive vs sectorLow risk
Next earnings report: Nov 9, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to 6.3% from -4.7% a year earlier.
- Earnings beat analyst estimates in each of the last 5 quarters (average surprise over the last four: +18.2%).
- The stock is in an uptrend: above its 200-day average for 288 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 47%
- FCF growth (TTM, YoY)Top 16%
- Revenue growth, 3-year CAGRTop 36%
- Revenue growth accelerationBottom 31%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 4%
- Gross marginBottom 15%
- Operating marginTop 32%
- Cash conversion (OCF / net income)Bottom 46%
- Accruals (lower is better)Top 46%
- Net debt / EBITDA (lower is better)Top 24%
- Interest coverTop 2%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 22%
- Free-cash-flow yieldTop 26%
- EBITDA / enterprise valueTop 25%
- Sales / enterprise valueTop 23%
- P/E vs own 5-year history (lower is better)Top 44%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 29%
- 6-month returnTop 46%
- 1-year return vs S&P 500Top 20%
- Distance from 52-week highTop 19%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 26%
- Consecutive EPS beatsTop 15%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 26%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 26%
- Maximum drawdown, 3 yearsTop 3%
- Beta vs S&P 500 (lower is better)Top 17%
- Net debt / EBITDA (lower is better)Top 24%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 13.5% | 10.3% | ↓ |
| Gross margin | 19.6% | 21.6% | ↑ |
| Operating margin | -4.7% | 6.3% | ↑ |
| FCF margin | 2.9% | 5.5% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 10.3% | 13.5% | ↓ | Top 47% |
| Gross margin | 21.6% | 19.6% | ↑ | Bottom 15% |
| Operating margin | 6.3% | -4.7% | ↑ | Top 32% |
| Net margin | 4.5% | -6.2% | ↑ | — |
| Free-cash-flow margin | 5.5% | 2.9% | ↑ | — |
| Return on invested capital | 21.5% | — | Top 4% | |
| Revenue growth, 3-year CAGR | 16.8% | — | Top 36% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.50×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -7.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 0.7%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -0.1 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.48×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 145.4×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.00%
- Shareholder yield
- 0.00%
- Share count change, 1 year
- +1.0%
- Share count change, 3-year CAGR
- +1.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 5
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +18.2%
- Average 2-day reaction, last 8
- -0.3%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $50.67
- Target vs current price
- +19.6%
- Analysts with a rating
- 4
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +10.8% | -2.5% | -4.7% | -3.6% | — |
| May 6, 2026 | +20.8% | -1.8% | -6.3% | +5.1% | +6.1% |
| Mar 11, 2026 | +37.0% | -0.4% | +1.3% | +19.0% | +21.2% |
| Nov 10, 2025 | +4.2% | +3.3% | +1.4% | -0.6% | +14.1% |
| Aug 11, 2025 | +4.5% | -0.5% | +18.3% | +44.5% | +41.6% |
| May 12, 2025 | -4.5% | +0.1% | -3.7% | -20.7% | -18.3% |
| Mar 26, 2025 | +14.3% | -0.5% | +3.3% | +15.7% | -1.1% |
| Nov 12, 2024 | -1152.6% | -0.3% | -3.9% | +9.3% | -4.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | $0.29 | $0.26 | +10.8% | $351.8M |
| May 6, 2026 | $0.29 | $0.24 | +20.8% | $336.6M |
| Mar 11, 2026 | $0.37 | $0.27 | +37.0% | $397.6M |
| Nov 10, 2025 | $0.25 | $0.24 | +4.2% | $377.4M |
| Aug 11, 2025 | $0.23 | $0.22 | +4.5% | $344.3M |
| May 12, 2025 | $0.21 | $0.22 | -4.5% | $329.3M |
| Mar 26, 2025 | $0.24 | $0.21 | +14.3% | $338.6M |
| Nov 12, 2024 | -$2.00 | $0.19 | -1152.6% | $314.4M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 41.1× | 43.5× | 38th | Top 22% |
| P/E (forward) | 32.6× | — | — | — |
| EV / EBITDA | 23.1× | — | — | Top 25% |
| EV / Sales | 1.80× | — | — | Top 23% |
| Free-cash-flow yield | 2.97% | — | — | Top 26% |
| Earnings yield | 2.43% | — | — | Top 22% |
P/E over the past five years
Range 21.1× – 72.7× since Jun 30, 2022. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 2
- Days above the 200-day average
- 288
- 50-day average slope (20 days)
- +2.7%
- 200-day average slope (20 days)
- +4.0%
- Distance from 50-day average
- +3.7%
- Distance from 200-day average
- +14.1%
- RSI (14)
- 52.3
- Relative volume
- 0.73×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 42.7%
- Volatility vs own 5-year history
- 37th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.52
- Correlation with S&P 500
- 0.18
- Current drawdown from 1-year high
- -11.7%
- Maximum drawdown, 3 years
- -27.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 12, 2024 | Mar 6, 2025 | -27.2% | 55 days | 40 days (May 2, 2025) |
| May 19, 2025 | Jun 17, 2025 | -25.8% | 20 days | 52 days (Sep 2, 2025) |
| Sep 11, 2025 | Oct 10, 2025 | -22.7% | 21 days | 22 days (Nov 11, 2025) |
| Aug 7, 2026 | Aug 28, 2026 | -15.4% | 15 days | 8 days (Sep 10, 2026) |
| Sep 15, 2026 | Sep 29, 2026 | -15.3% | 10 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $2.68B
- P/E (TTM)
- 41.1
- EPS, diluted (TTM)
- $1.03
- Revenue (TTM)
- $1.46B
- 52-week range
- $23.14 – $48.33
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $792.1M | $908.9M | $1.05B | $1.23B | $1.45B |
| Gross profit | $161.3M | $185.9M | $208.3M | $244.4M | $282.0M |
| Operating income | $30.1M | $52.0M | $40.9M | -$62.9M | $88.9M |
| Net income | $16.3M | $35.4M | $23.9M | -$87.3M | $49.2M |
| EPS (diluted) | $0.27 | $0.58 | $0.39 | -$1.77 | $0.78 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $314.4M | $338.6M | $329.3M | $344.3M | $377.4M | $397.6M | $336.6M | $351.8M |
| Net income | -$112.6M | $11.9M | $9.4M | $9.0M | $9.8M | $20.9M | $13.3M | $21.9M |
| EPS (diluted) | -$2.00 | $0.20 | $0.15 | $0.14 | $0.15 | $0.33 | $0.21 | $0.34 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $58.5M | $48.5M | $70.8M | $58.0M | $100.3M |
| Capital expenditure | -$9.3M | -$16.8M | -$14.6M | -$16.4M | -$19.6M |
| Free cash flow | $49.2M | $31.8M | $56.3M | $41.6M | $80.7M |
| Dividends paid | -$17.4M | -$30.8M | -$38.4M | -$35.8M | $0 |
| Net share buybacks | $0 | $0 | $0 | $64.6M | -$1.6M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $89.8M
- Total assets
- $443.6M
- Total liabilities
- $185.9M
- Total debt
- $35.2M
- Net debt
- -$54.6M
- Shareholders’ equity
- $245.6M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 2,427,722
- Days to cover
- 3.73
- Change vs previous report
- -20.2%
FINRA short interest, settlement date Sep 15, 2026.